Pang, Wenzhe, Wu, Yarong, Xue, Na, Li, Ying, Du, Shuang, He, Binnan, Yang, Caiqin, Wang, Jing, and Zeng, Yanli
The binding mechanism and binding forces of API-CCF cocrystal with BSA and cell inhibitory rates vary with the kinds of weak forces between API and CCF. • Novel curcumine(CUR)-isonicotinamide (1) and CUR-gallic acid (2) cocrystals were prepared. • C O and O H groups in CUR involved in the hydrogen bonds in cocrystal 1 and 2, respectively. • Hydrogen bonds and/or van der Waals forces occurred between cocrystal 1 and BSA binding reaction. • Hydrophobic forces occurred in the binding reaction with BSA for cocrystal 2. • Cell inhibitory rates of cocrystal 1 differed from that of cocrystal 2. Screening of cocrystal has been proved to be a powerful approach to improve the solubility, dissolution rate and even the bioavailability of poorly water-soluble active pharmaceutical ingredient (API). Typically, the formation of cocrystal induces no change on the pharmacological profile of the APIs. However, so far, it is not clear whether a cocrystal would induce changes in biological profiles of API and, if so, which factors induce those changes. To clarify these aspects, two CUR-isonicotinamide (cocrystal 1) and CUR-gallic acid (cocrystal 2) cocrystals with enhanced physical properties and pharmacokinetic profile for potential pharmaceutical application were screened. We focused on the effects of the type of hydrogen bonds occurred in cocrystal on the binding between cocrystal and BSA as well as cell inhibiting activity. The appearance of new peaks in the X-ray powder diffraction (PXRD) and a single different melting point in the differential scanning calorimetry (DSC) measurements revealed that homogeneous, single phase formulations were obtained by forming cocrystals between CUR and coformers in a 1:2 M ratio. The results of Fourier-transform infrared and solid-state 13C nuclear magnetic resonance spectra as well as density function theory simulation indicated that different hydrogen bonds were formed in two cocrystal, which were the C O⋯H N hydrogen bond between the C O group in CUR and the N H groups in isonicotinamide in cocrystal 1, and C O⋯H O hydrogen bond between phenol O H group in CUR and the C O group in gallic acid in cocrystal 2, respectively. Interestingly, the different type of weak interactions in cocrystal induced various binding pattern between cocrystal and BSA and cancer cell cytotoxicity supported by fluorescence spectroscopy and MTT assay in vitro. It was reasonable that the affinity of cocrystal for proteins varied with specific and concerted weak interactions in cocrystal, which would induce changes in the biological profiles of the parent drug. Furthermore, in vivo pharmacokinetics of CUR and CUR-based cocrystals in SD rats were evaluated through UPLC-MS/MS method. Compared with intact CUR, the pharmacokinetics parameters C max , T max , AUC 0-t and AUC 0-∞ of CUR-based cocrystals were improved (P < 0.05); C max increased 30-fold, T max shortened 6-fold, and AUC 0-t increased 6-fold. Overall, the present results inferred different effects induced by cocrystals on a biologic system, not only bioavailability but biological profiles. [ABSTRACT FROM AUTHOR]